Eli Lilly & Co (LLY) - Neuroscience Revenue (I:ELCLYQML)
Level Chart
Basic Info
|
Eli Lilly & Co (LLY) - Neuroscience Revenue is at a current level of 315.70M, down from 344.00M last quarter and down from 351.80M one year ago. This is a change of -8.23% from last quarter and -10.26% from one year ago. |
|
Neuroscience Revenue refers to the total revenue generated by Eli Lilly & Co from its products and treatments related to neuroscience within a specific reporting period. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 315.70M |
| Latest Period | Sep 2025 |
| Last Updated | Dec 18 2025, 15:08 EST |
| Next Release | Feb 27 2026, 08:30 EST (E) |
| Average Growth Rate | 39.90% |
| Value from Last Quarter | 344.00M |
| Change from Last Quarter | -8.23% |
| Value from 1 Year Ago | 351.80M |
| Change from 1 Year Ago | -10.26% |
| Frequency | Quarterly |
| Unit | USD |
| Adjustment | N/A |
| Download Source File | Upgrade |
Historical Data
| Date | Value |
|---|---|
| September 30, 2025 | 315.70M |
| June 30, 2025 | 344.00M |
| March 31, 2025 | 272.10M |
| December 31, 2024 | 393.10M |
| September 30, 2024 | 351.80M |
| June 30, 2024 | 339.50M |
| March 31, 2024 | 389.10M |
| December 31, 2023 | 362.80M |
| September 30, 2023 | 1.768B |
| June 30, 2023 | 387.20M |
| March 31, 2023 | 360.50M |
| December 31, 2022 | 385.30M |
| Date | Value |
|---|---|
| September 30, 2022 | 373.20M |
| June 30, 2022 | 390.00M |
| March 31, 2022 | 397.70M |
| December 31, 2021 | 470.60M |
| September 30, 2021 | 450.10M |
| June 30, 2021 | 512.20M |
| March 31, 2021 | 465.40M |
| December 31, 2020 | 474.60M |
| September 30, 2020 | 470.70M |
| June 30, 2020 | 422.50M |
| March 31, 2020 | 463.50M |
| December 31, 2019 | 676.00M |
News
Basic Info
|
Eli Lilly & Co (LLY) - Neuroscience Revenue is at a current level of 315.70M, down from 344.00M last quarter and down from 351.80M one year ago. This is a change of -8.23% from last quarter and -10.26% from one year ago. |
|
Neuroscience Revenue refers to the total revenue generated by Eli Lilly & Co from its products and treatments related to neuroscience within a specific reporting period. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 315.70M |
| Latest Period | Sep 2025 |
| Last Updated | Dec 18 2025, 15:08 EST |
| Next Release | Feb 27 2026, 08:30 EST (E) |
| Average Growth Rate | 39.90% |
| Value from Last Quarter | 344.00M |
| Change from Last Quarter | -8.23% |
| Value from 1 Year Ago | 351.80M |
| Change from 1 Year Ago | -10.26% |
| Frequency | Quarterly |
| Unit | USD |
| Adjustment | N/A |
| Download Source File | Upgrade |